Fraud Investigation: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Shareholders Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.
Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review process in terms that conveyed optimism about the likelihood of FDA approval. The Company's August 19, 2025 8-K filing and subsequent public communications continued to present the reproxalap program as a central focus of its pipeline and a key driver of near-term commercial potential.
The FDA's Complete Response Letter on March 17, 2026 stated that reproxalap had not demonstrated sufficient efficacy. Prior to the CRL, the Company's public statements emphasized positive aspects of the drug's clinical data and regulatory prospects. Levi & Korsinsky is investigating whether Aldeyra failed to disclose material information about efficacy risks that would have altered the forward-looking picture presented to shareholders.
If you suffered a loss on your Aldeyra Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290277
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
Fraud Investigation: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Shareholders
2026-03-27 3:38 PM EDT
Did You Suffer Losses in ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky About Securities Fraud Claims
2026-03-27 11:50 AM EDT
Fraud Investigation Opened: Levi & Korsinsky Investigates Freshpet, Inc. (FRPT) on Behalf of Shareholders
2026-03-25 9:47 AM EDT
Sep 29, 2025
AI isn’t just a future trend. It’s already reshaping how press releases are read, shared, and discovered today. The audience for your news is no longer only human. Journalists, analysts, and investors still matter, but now AI systems are scanning, indexing, and summarizing your announcements at scale. Here are a few numbers that show the size of this shift: 78% of companies now use AI in at least one function ( McKinsey, 2025 ) 92% of Fortune 500 companies are using OpenAI's technology (...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services